Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025

Udgivet den 10-03-2025  |  kl. 17:00  |  

ORION CORPORATION
STOCK EXCHANGE RELEASE - CHANGES IN COMPANY'S OWN SHARES
10 MARCH 2025 at 19.00 EET           

Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025

In accordance with a decision by the Board of Directors, Orion Corporation has on 10 March 2025 transferred altogether 191,911 Orion Corporation B shares held by the company as a share reward for earning period 2022-2024 and a reward for commitment part to the persons belonging to the Share-based Incentive Plan of Orion Group. The transfer is based on the authorisation by the Annual General Meeting of 23 March 2022.

The price per share of the transferred shares is EUR 53.7158, which is the volume weighted average quotation of the Orion Corporation B share on 10 March 2025. Accordingly, the total transaction price of the transferred shares is EUR 10,308,652.89.

After the share transfer, the total number of own B shares held by Orion Corporation is 440,944.

Orion Corporation has informed about the Share-based Incentive Plan in stock exchange release on 10 February 2022.


Orion Corporation

Liisa Hurme
President and CEO
    Olli Huotari
EVP, Corporate Functions
 

                                                 
Contact person:
Olli Huotari, EVP, Corporate Functions
tel. +358 10 426 3054

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orionpharma.com

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2024 amounted to EUR 1,542 million and the company had about 3,700 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.


\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

09:26 Aktier/åbning: Udsalg i Genmab og Novo fortsætter på ny blodrød dag for eliteindeks
09:14 Britiske byggeaktier er i hopla efter regeringsforslag
09:02 Genmab: Oversigt over analytikernes ændringer efter Johnson & Johnson-melding
08:42 Genmab bliver sænket til "hold" af Sydbank: Mangler kurstriggere på kort sigt
08:40 Råvarer: Oliepriserne stiger trods hav af bekymringer
08:22 Carlsberg sænkes til "hold" hos Jyske Bank efter stærk årsstart
08:18 Aktier/tendens: Rød dag i vente efter voldsom amerikansk nedtur - Novo og Genmab i fokus
08:03 Norsk storbank og Genmab: Fokus fremtid efter partners beslutning om Hexabody
07:53 Genmab får skåret kursmålet til 2300 kr. fra 2500 kr. af SEB efter kursklø
07:46 Tysklands De Grønne ser mulighed for finanspolitisk aftale inden ugen er omme
07:25 Trump kommer Elon Musk til undsætning: Vil købe en "splinterny Tesla"
07:17 Obligationer/tendens: Renter kan dykke efter ny Trump-panik og før jobtal
07:05 Danske Bank forventer blodrøde markeder efter største aktieudsalg i over to år
06:40 Asien: Frygt for at Trumps toldregime ender i recession dominerer
06:34 Genmabs kursmålet sænkes 10 pct. af Truist
06:34 Genmab får skåret kursmålet hos Deutsche Bank efter Hexabody-melding
06:34 Rockwool får højere kursmål hos JPMorgan
06:34 Genmabs topchef: Har flere opkøbsmål på radaren
06:32 Asien: Frygt for at Trumps toldregime ender i recession dominerer
06:32 Valuta: Aggressiv amerikansk told frygtes at lægge USA's økonomiske vækst i graven